2023
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrialsThe functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium
Bruin W, Abe Y, Alonso P, Anticevic A, Backhausen L, Balachander S, Bargallo N, Batistuzzo M, Benedetti F, Bertolin Triquell S, Brem S, Calesella F, Couto B, Denys D, Echevarria M, Eng G, Ferreira S, Feusner J, Grazioplene R, Gruner P, Guo J, Hagen K, Hansen B, Hirano Y, Hoexter M, Jahanshad N, Jaspers-Fayer F, Kasprzak S, Kim M, Koch K, Bin Kwak Y, Kwon J, Lazaro L, Li C, Lochner C, Marsh R, Martínez-Zalacaín I, Menchon J, Moreira P, Morgado P, Nakagawa A, Nakao T, Narayanaswamy J, Nurmi E, Zorrilla J, Piacentini J, Picó-Pérez M, Piras F, Piras F, Pittenger C, Reddy J, Rodriguez-Manrique D, Sakai Y, Shimizu E, Shivakumar V, Simpson B, Soriano-Mas C, Sousa N, Spalletta G, Stern E, Evelyn Stewart S, Szeszko P, Tang J, Thomopoulos S, Thorsen A, Yoshida T, Tomiyama H, Vai B, Veer I, Venkatasubramanian G, Vetter N, Vriend C, Walitza S, Waller L, Wang Z, Watanabe A, Wolff N, Yun J, Zhao Q, van Leeuwen W, van Marle H, van de Mortel L, van der Straten A, van der Werf Y, Thompson P, Stein D, van den Heuvel O, van Wingen G. The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium. Molecular Psychiatry 2023, 28: 4307-4319. PMID: 37131072, PMCID: PMC10827654, DOI: 10.1038/s41380-023-02077-0.Peer-Reviewed Original ResearchObsessive-compulsive disorderHealthy controlsFunctional connectivitySensorimotor networkOCD patientsResting-state functional connectivityWhole-brain functional connectivityResting-state connectivityPathophysiological modelPatient statusAccurate biomarkersWidespread abnormalitiesPatientsMajority of studiesEntire brainGeneralizability of resultsGroup differencesFunctional connectomeAbnormalitiesBiomarkersFunctional networksDisordersCurrent knowledgeIndividual levelIndependent samples
2024
Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchWhite matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
Kim B, Kim G, Abe Y, Alonso P, Ameis S, Anticevic A, Arnold P, Balachander S, Banaj N, Bargalló N, Batistuzzo M, Benedetti F, Bertolín S, Beucke J, Bollettini I, Brem S, Brennan B, Buitelaar J, Calvo R, Castelo-Branco M, Cheng Y, Chhatkuli R, Ciullo V, Coelho A, Couto B, Dallaspezia S, Ely B, Ferreira S, Fontaine M, Fouche J, Grazioplene R, Gruner P, Hagen K, Hansen B, Hanna G, Hirano Y, Höxter M, Hough M, Hu H, Huyser C, Ikuta T, Jahanshad N, James A, Jaspers-Fayer F, Kasprzak S, Kathmann N, Kaufmann C, Kim M, Koch K, Kvale G, Kwon J, Lazaro L, Lee J, Lochner C, Lu J, Manrique D, Martínez-Zalacaín I, Masuda Y, Matsumoto K, Maziero M, Menchón J, Minuzzi L, Moreira P, Morgado P, Narayanaswamy J, Narumoto J, Ortiz A, Ota J, Pariente J, Perriello C, Picó-Pérez M, Pittenger C, Poletti S, Real E, Reddy Y, van Rooij D, Sakai Y, Sato J, Segalas C, Shavitt R, Shen Z, Shimizu E, Shivakumar V, Soreni N, Soriano-Mas C, Sousa N, Sousa M, Spalletta G, Stern E, Stewart S, Szeszko P, Thomas R, Thomopoulos S, Vecchio D, Venkatasubramanian G, Vriend C, Walitza S, Wang Z, Watanabe A, Wolters L, Xu J, Yamada K, Yun J, Zarei M, Zhao Q, Zhu X, Thompson P, Bruin W, van Wingen G, Piras F, Piras F, Stein D, van den Heuvel O, Simpson H, Marsh R, Cha J. White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group. Molecular Psychiatry 2024, 29: 1063-1074. PMID: 38326559, PMCID: PMC11176060, DOI: 10.1038/s41380-023-02392-6.Peer-Reviewed Original ResearchObsessive-compulsive disorderNeurobiology of obsessive-compulsive disorderDiffusion tensor imagingENIGMA-OCD working groupClassification of obsessive-compulsive disorderGray matter morphometryWhite matter integrityCross-site generalizabilityHealthy controlsWhite matter pathwaysPosterior thalamic radiationWhite matter featuresMachine learning findingsLeave-one-site-out cross-validationOCD studiesThalamic radiationMedication effectsMultivariate patternsAdult participantsTensor imagingLearning interpretationNeurobiologyCorpus callosumLearning findingsInternal capsuleSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatment